METABOLIC PROTECTIVE EFFECT OF WOBENZYM IN AN EXPERIMENTAL MODEL OF ACUTE KIDNEY INJURY
Abstract
Acute kidney injury (AKI) is a pathological condition characterized by a sharp decline in kidney function, leading to metabolic disturbances and the accumulation of toxic substances in the body. One of the key approaches in AKI treatment is metabolic protection of the kidneys. Various drugs, including Wobenzym and dopamine, are being used for this purpose. Wobenzym is a drug containing a complex of enzymes with anti-inflammatory and immunomodulatory properties. This study aimed to investigate the protective effects of Wobenzym in an experimental model of AKI.
References
Mehta RL, et al. "Acute kidney injury: definitions, pathophysiology, and management." The Lancet. 2020.
Bellomo R, et al. "Acute renal failure—definition, outcome measures, animal models, fluid therapy, and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group." Critical Care. 2019.
Laterza OF, et al. "Cystatin C as a biomarker of acute kidney injury in the intensive care setting." Critical Care Medicine. 2021.
Dharnidharka VR, et al. "Serum cystatin C as a marker of renal function: a review." American Journal of Kidney Diseases. 2022.
World Health Organization. "Guidelines for the care and use of laboratory animals in research." WHO Report. 2020.
Heyman SN, et al. "Glycerol-induced acute renal failure: a model for ischemic renal injury in rats." Nephron. 2019.
National Kidney Foundation, Inc2021. 12-10-4004_ABE
Mehta RL, Cerdá J, Burdmann EA, et al. "International Society of Nephrology: O‘tkir buyrak zararlanishi diagnostikasi." Kidney International, 2016.
Susantitaphong P, Cruz DN, Cerda J, et al. "Treatment strategies for acute kidney injury." Nephrology Dialysis Transplantation, 2020.
Chertow GM, Burdick E, Honour M, et al. "Acute kidney injury, mortality, length of stay, and costs in hospitalized patients." Journal of the American Society of Nephrology, 2015.
